Cutaneous manifestations of highly active antiretroviral therapy

Deborah B. Henderson, Clay J Cockerell

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

The introduction of combination antiretroviral drug therapy in the mid 1990s resulted in a dramatic decrease in morbidity and mortality among patients infected with human the immunodeficiency virus (HIV).1 These drug combinations, referred to as highly active antiretroviral therapy (HAART), have been shown to reduce viral replication significantly and reconstitute CD4+ lymphocyte counts in HIVpositive patients.2 The drugs that comprise HAART regimens are categorized by their distinct mechanisms of action into four main groups: Non-nucleoside reverse transcriptase inhibitors (NNRTIs), nucleoside reverse transcriptase inhibitors (NRTIs), protease inhibitors (PIs), and fusion or entry inhibitors. Since their implementation, the overall utility of these medications has been complicated by an increasing number of adverse drug reactions that have become recognized. Documented cutaneous side-effects such as pigmentation disorders, urticarial eruptions, and hypersensitivity reactions have all been associated with HAART therapy. In addition, a common adverse effect is a syndrome of hyperlipidemia, abnormal fat distribution, and glucose intolerance known as the lipodystrophy syndrome.3 Such sideeffects have substantially diminished compliance with antiretroviral medications and pose a problem for their continued use.4.

Original languageEnglish (US)
Title of host publicationCutaneous Manifestations of HIV Disease
PublisherCRC Press
Pages84-93
Number of pages10
ISBN (Electronic)9781840766042
ISBN (Print)9781840761429
DOIs
StatePublished - Jan 1 2012

Fingerprint

Skin Manifestations
Highly Active Antiretroviral Therapy
Reverse Transcriptase Inhibitors
Pigmentation Disorders
Lipodystrophy
Glucose Intolerance
Drug Combinations
CD4 Lymphocyte Count
Hyperlipidemias
Combination Drug Therapy
Protease Inhibitors
Drug-Related Side Effects and Adverse Reactions
Nucleosides
Hypersensitivity
Fats
HIV
Morbidity
Skin
Mortality
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Henderson, D. B., & Cockerell, C. J. (2012). Cutaneous manifestations of highly active antiretroviral therapy. In Cutaneous Manifestations of HIV Disease (pp. 84-93). CRC Press. https://doi.org/10.1201/b15910

Cutaneous manifestations of highly active antiretroviral therapy. / Henderson, Deborah B.; Cockerell, Clay J.

Cutaneous Manifestations of HIV Disease. CRC Press, 2012. p. 84-93.

Research output: Chapter in Book/Report/Conference proceedingChapter

Henderson, DB & Cockerell, CJ 2012, Cutaneous manifestations of highly active antiretroviral therapy. in Cutaneous Manifestations of HIV Disease. CRC Press, pp. 84-93. https://doi.org/10.1201/b15910
Henderson DB, Cockerell CJ. Cutaneous manifestations of highly active antiretroviral therapy. In Cutaneous Manifestations of HIV Disease. CRC Press. 2012. p. 84-93 https://doi.org/10.1201/b15910
Henderson, Deborah B. ; Cockerell, Clay J. / Cutaneous manifestations of highly active antiretroviral therapy. Cutaneous Manifestations of HIV Disease. CRC Press, 2012. pp. 84-93
@inbook{cb1353b3ff0949709ce817b2999d0c3f,
title = "Cutaneous manifestations of highly active antiretroviral therapy",
abstract = "The introduction of combination antiretroviral drug therapy in the mid 1990s resulted in a dramatic decrease in morbidity and mortality among patients infected with human the immunodeficiency virus (HIV).1 These drug combinations, referred to as highly active antiretroviral therapy (HAART), have been shown to reduce viral replication significantly and reconstitute CD4+ lymphocyte counts in HIVpositive patients.2 The drugs that comprise HAART regimens are categorized by their distinct mechanisms of action into four main groups: Non-nucleoside reverse transcriptase inhibitors (NNRTIs), nucleoside reverse transcriptase inhibitors (NRTIs), protease inhibitors (PIs), and fusion or entry inhibitors. Since their implementation, the overall utility of these medications has been complicated by an increasing number of adverse drug reactions that have become recognized. Documented cutaneous side-effects such as pigmentation disorders, urticarial eruptions, and hypersensitivity reactions have all been associated with HAART therapy. In addition, a common adverse effect is a syndrome of hyperlipidemia, abnormal fat distribution, and glucose intolerance known as the lipodystrophy syndrome.3 Such sideeffects have substantially diminished compliance with antiretroviral medications and pose a problem for their continued use.4.",
author = "Henderson, {Deborah B.} and Cockerell, {Clay J}",
year = "2012",
month = "1",
day = "1",
doi = "10.1201/b15910",
language = "English (US)",
isbn = "9781840761429",
pages = "84--93",
booktitle = "Cutaneous Manifestations of HIV Disease",
publisher = "CRC Press",

}

TY - CHAP

T1 - Cutaneous manifestations of highly active antiretroviral therapy

AU - Henderson, Deborah B.

AU - Cockerell, Clay J

PY - 2012/1/1

Y1 - 2012/1/1

N2 - The introduction of combination antiretroviral drug therapy in the mid 1990s resulted in a dramatic decrease in morbidity and mortality among patients infected with human the immunodeficiency virus (HIV).1 These drug combinations, referred to as highly active antiretroviral therapy (HAART), have been shown to reduce viral replication significantly and reconstitute CD4+ lymphocyte counts in HIVpositive patients.2 The drugs that comprise HAART regimens are categorized by their distinct mechanisms of action into four main groups: Non-nucleoside reverse transcriptase inhibitors (NNRTIs), nucleoside reverse transcriptase inhibitors (NRTIs), protease inhibitors (PIs), and fusion or entry inhibitors. Since their implementation, the overall utility of these medications has been complicated by an increasing number of adverse drug reactions that have become recognized. Documented cutaneous side-effects such as pigmentation disorders, urticarial eruptions, and hypersensitivity reactions have all been associated with HAART therapy. In addition, a common adverse effect is a syndrome of hyperlipidemia, abnormal fat distribution, and glucose intolerance known as the lipodystrophy syndrome.3 Such sideeffects have substantially diminished compliance with antiretroviral medications and pose a problem for their continued use.4.

AB - The introduction of combination antiretroviral drug therapy in the mid 1990s resulted in a dramatic decrease in morbidity and mortality among patients infected with human the immunodeficiency virus (HIV).1 These drug combinations, referred to as highly active antiretroviral therapy (HAART), have been shown to reduce viral replication significantly and reconstitute CD4+ lymphocyte counts in HIVpositive patients.2 The drugs that comprise HAART regimens are categorized by their distinct mechanisms of action into four main groups: Non-nucleoside reverse transcriptase inhibitors (NNRTIs), nucleoside reverse transcriptase inhibitors (NRTIs), protease inhibitors (PIs), and fusion or entry inhibitors. Since their implementation, the overall utility of these medications has been complicated by an increasing number of adverse drug reactions that have become recognized. Documented cutaneous side-effects such as pigmentation disorders, urticarial eruptions, and hypersensitivity reactions have all been associated with HAART therapy. In addition, a common adverse effect is a syndrome of hyperlipidemia, abnormal fat distribution, and glucose intolerance known as the lipodystrophy syndrome.3 Such sideeffects have substantially diminished compliance with antiretroviral medications and pose a problem for their continued use.4.

UR - http://www.scopus.com/inward/record.url?scp=85055553363&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055553363&partnerID=8YFLogxK

U2 - 10.1201/b15910

DO - 10.1201/b15910

M3 - Chapter

AN - SCOPUS:85055553363

SN - 9781840761429

SP - 84

EP - 93

BT - Cutaneous Manifestations of HIV Disease

PB - CRC Press

ER -